|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions |
ISO |
hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl] |
CTD |
PMID:28595002 |
|
NCBI chr10:106,006,404...106,008,294
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of hexanoic acid |
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
|
G |
A2m |
alpha-2-macroglobulin |
decreases expression |
ISO |
Aminocaproic Acid results in decreased expression of A2M protein |
CTD |
PMID:11304663 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Folh1 |
folate hydrolase 1 |
multiple interactions |
ISO |
[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [isospaglumic acid binds to FOLH1 protein] |
CTD |
PMID:24508213 |
|
NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379
|
|
G |
Grpr |
gastrin releasing peptide receptor |
multiple interactions |
ISO |
[2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [bombesin, Tyr(4)- binds to GRPR protein] |
CTD |
PMID:24508213 |
|
NCBI chr X:30,998,425...31,038,442
Ensembl chr X:30,998,416...31,038,442
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17482686 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17482686 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Plg |
plasminogen |
multiple interactions |
ISO |
Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK1 protein]; Aminocaproic Acid inhibits the reaction [PLG protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17482686 |
|
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
|
|
G |
Serpinc1 |
serpin family C member 1 |
increases expression |
ISO |
Aminocaproic Acid results in increased expression of SERPINC1 protein |
CTD |
PMID:11304663 |
|
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
|
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases export |
ISO |
SLCO4C1 protein results in increased export of Homoarginine |
CTD |
PMID:30865704 |
|
NCBI chr 9:97,180,162...97,229,135
Ensembl chr 9:97,178,861...97,229,715
|
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] |
CTD |
PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
ISO |
Lisinopril analog results in decreased activity of ACE protein |
CTD |
PMID:22200082 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases expression multiple interactions increases activity |
EXP ISO |
Lisinopril results in increased expression of ACE2 mRNA ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)] Lisinopril results in increased activity of ACE2 protein |
CTD |
PMID:15897343 PMID:16221218 PMID:27649628 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein] Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein] |
CTD |
PMID:23060470 PMID:31710167 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions affects metabolic processing decreases secretion increases secretion affects response to substance increases expression |
ISO EXP |
Lisinopril results in decreased expression of AGT protein [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)] [[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein [Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA Lisinopril results in decreased secretion of AGT protein Lisinopril results in increased secretion of AGT protein alternative form AGT gene alternative form affects the susceptibility to Lisinopril Lisinopril results in increased expression of AGT mRNA |
CTD |
PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 PMID:27649628 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Lisinopril results in decreased expression of BCL2 |
CTD |
PMID:10075388 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Cd2ap |
CD2-associated protein |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] |
CTD |
PMID:16636307 |
|
NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199
|
|
G |
Edn1 |
endothelin 1 |
decreases secretion |
ISO |
Lisinopril results in decreased secretion of EDN1 protein |
CTD |
PMID:19079593 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] |
CTD |
PMID:20051877 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] |
CTD |
PMID:19225054 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hpse |
heparanase |
multiple interactions |
EXP |
[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] |
CTD |
PMID:19429930 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Lisinopril results in increased expression of IGFBP1 protein |
CTD |
PMID:9663927 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] |
CTD |
PMID:20051877 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] |
CTD |
PMID:23060470 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] |
CTD |
PMID:20051877 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] |
CTD |
PMID:16636307 PMID:19293598 |
|
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
multiple interactions |
EXP |
Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] |
CTD |
PMID:16636307 |
|
NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Lisinopril results in decreased expression of NPPA protein |
CTD |
PMID:8393685 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Ren |
renin |
increases expression multiple interactions |
ISO EXP |
Lisinopril results in increased expression of REN protein [Lisinopril co-treated with Losartan] results in increased expression of REN mRNA Lisinopril results in increased expression of REN mRNA |
CTD |
PMID:2550029 PMID:8915971 PMID:16221218 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
Lisinopril affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] |
CTD |
PMID:20051877 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] |
CTD |
PMID:19293598 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of ACOT1 mRNA |
CTD |
PMID:19407336 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of ACSL1 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Apoa2 |
apolipoprotein A2 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of APOA2 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoa4 |
apolipoprotein A4 |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of APOA4 mRNA |
CTD |
PMID:22071372 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoa5 |
apolipoprotein A5 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of APOA5 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 8:46,561,180...46,563,818
Ensembl chr 8:46,561,229...46,563,816
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
perfluorohexanoic acid promotes the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:29601859 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
perfluorohexanoic acid results in decreased expression of CCND1 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of CPT1A mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of CPT1B mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of CYP2B6 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of CYP4A1 mRNA |
CTD |
PMID:19407336 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
perfluorohexanoic acid results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of EHHADH mRNA |
CTD |
PMID:23567314 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of FABP1 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of FDFT1 mRNA |
CTD |
PMID:22071372 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
increases expression decreases expression |
ISO EXP |
perfluorohexanoic acid results in increased expression of HADHA mRNA perfluorohexanoic acid results in decreased expression of HADHA mRNA |
CTD |
PMID:22071372 PMID:23567314 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of HADHB mRNA |
CTD |
PMID:22071372 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hhex |
hematopoietically expressed homeobox |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of HHEX mRNA |
CTD |
PMID:22071372 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Mbl2 |
mannose binding lectin 2 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of MBL2 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 1:228,016,439...228,024,736
|
|
G |
Mogat1 |
monoacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of MOGAT1 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 9:79,980,963...79,988,513
Ensembl chr 9:79,956,649...79,988,513
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of NOS2 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
perfluorohexanoic acid results in increased activity of NR1I2 protein |
CTD |
PMID:28115241 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pax8 |
paired box 8 |
increases expression |
EXP |
perfluorohexanoic acid results in increased expression of PAX8 mRNA |
CTD |
PMID:22071372 |
|
NCBI chr 3:7,185,721...7,242,363
Ensembl chr 3:7,185,723...7,242,363
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of PDK4 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of PLIN2 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 5:101,156,643...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of POR mRNA |
CTD |
PMID:23567314 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases activity multiple interactions increases expression |
ISO |
perfluorohexanoic acid results in increased activity of PPARA protein [perfluorooctanoic acid co-treated with perfluorohexanoic acid] results in increased expression of PPARA mRNA perfluorohexanoic acid results in increased expression of PPARA mRNA |
CTD |
PMID:23391484 PMID:24374136 PMID:28857218 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of PPARD mRNA |
CTD |
PMID:23567314 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity |
ISO |
perfluorohexanoic acid results in increased activity of PPARG protein |
CTD |
PMID:23391484 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
multiple interactions |
ISO |
perfluorohexanoic acid binds to and results in decreased activity of PTPN11 protein |
CTD |
PMID:27572461 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of SCD mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
perfluorohexanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid] |
CTD |
PMID:19915082 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of SLC25A34 mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 5:153,932,081...153,936,854
|
|
G |
Ttr |
transthyretin |
multiple interactions |
ISO |
perfluorohexanoic acid affects the reaction [Thyroxine binds to TTR protein] |
CTD |
PMID:27528273 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
ISO |
perfluorohexanoic acid results in increased expression of TXNIP mRNA |
CTD |
PMID:23567314 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] |
CTD |
PMID:30896085 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] |
CTD |
PMID:30896085 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein] |
CTD |
PMID:20369241 PMID:30896085 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity affects binding |
ISO |
Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein] royal jelly results in increased activity of ESR1 protein |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions affects binding |
ISO |
Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] |
CTD |
PMID:30896085 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
royal jelly results in increased expression of TFF1 mRNA |
CTD |
PMID:15946813 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] |
CTD |
PMID:30896085 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO EXP |
royal jelly results in increased expression of VEGFA mRNA |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|